SEC FIlings Archives - Page 2 of 19

27 Mar

SEC FIlings

Additional definitive proxy soliciting materials and Rule 14(a)(12)

March 27, 2023
Posted by Ulisses

21 Mar

SEC FIlings

Prospectus [Rule 424(b)(3)]

March 21, 2023
Posted by Ulisses

21 Mar

SEC FIlings

Prospectus [Rule 424(b)(3)]

March 21, 2023
Posted by Ulisses

21 Mar

SEC FIlings

Prospectus [Rule 424(b)(3)]

March 21, 2023
Posted by Ulisses

21 Mar

SEC FIlings

Current report

March 21, 2023
Posted by Ulisses

20 Mar

SEC FIlings

Prospectus [Rule 424(b)(3)]

March 20, 2023
Posted by Ulisses

17 Mar

SEC FIlings

Notice of Effectiveness

March 20, 2023
Posted by Ulisses

17 Mar

SEC FIlings

Notice of Effectiveness

March 20, 2023
Posted by Ulisses

17 Mar

SEC FIlings

Prospectus [Rule 424(b)(3)]

March 17, 2023
Posted by Ulisses

17 Mar

SEC FIlings

Prospectus [Rule 424(b)(3)]

March 17, 2023
Posted by Ulisses

SEC FIlings

Additional definitive proxy soliciting materials and Rule 14(a)(12)

Prospectus [Rule 424(b)(3)]

Prospectus [Rule 424(b)(3)]

Prospectus [Rule 424(b)(3)]

Current report

Prospectus [Rule 424(b)(3)]

Notice of Effectiveness

Notice of Effectiveness

Prospectus [Rule 424(b)(3)]

Prospectus [Rule 424(b)(3)]

test according

Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The Fiscal Year Ended December 31, 2023, Based On Currently Available Information

Scilex Holding Company Announces Filing of a New Drug Submission (NDS) to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without

Scilex Holding Company Announces that According to Prescription Data from Symphony Health, ZTlido® is the Most Prescribed Non-Opioid Branded Pain Treatment By Pain Specialists